Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Large Decrease in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the recipient of a significant decline in short interest in July. As of July 15th, there was short interest totaling 80,592 shares, a decline of 43.7% from the June 30th total of 143,052 shares. Approximately 6.8% of the company’s stock are short sold. Based on an average trading volume of 183,392 shares, the days-to-cover ratio is currently 0.4 days.

Regentis Biomaterials Price Performance

Regentis Biomaterials stock traded up $0.04 during midday trading on Wednesday, hitting $1.82. 44,581 shares of the company’s stock were exchanged, compared to its average volume of 2,434,301. The business’s 50-day moving average price is $2.97. Regentis Biomaterials has a 12 month low of $1.23 and a 12 month high of $15.50.

Hedge Funds Weigh In On Regentis Biomaterials

An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new position in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials as of its most recent SEC filing.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.